Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04039867 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer

A Phase 2 study, sponsored by University of California, Irvine.

Terminated
Registry status
Phase 2
Development phase
17
Enrollment target

NCT04039867 is a Phase 2 study that was terminated before completion, run by University of California, Irvine. The registered enrollment target is 17 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04039867, a Phase 2 study, was terminated before completion, sponsored by University of California, Irvine.

TERMINATED
Registry status
Phase 2
Development phase
17 participants
Enrollment target

Study Summary

This phase II trial evaluated the impact of Oxaliplatin and Gemcitabine in patients with recurrent or advanced transitional cell carcinoma of the bladder. The combination of Oxaliplatin and Gemcitabine is considered investigational and this study will help in determining if their activity and toxicity profiles are comparable or better than the standard regimens.

Interventions

  • DRUG Oxaliplatin with Gemcitabine

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2005-01-20
Est. Completion 2011-10-06
Phase Phase 2

Sponsor

University of California, Irvine

368 total trials

What the Registry Record Tells You About NCT04039867

The ClinicalTrials.gov registry entry for NCT04039867 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Oxaliplatin with Gemcitabine is the first listed.

NCT04039867 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04039867 about?

NCT04039867 is a clinical study titled "Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer". This phase II trial evaluated the impact of Oxaliplatin and Gemcitabine in patients with recurrent or advanced transitional cell carcinoma of the bladder. The combination of Oxaliplatin and Gemcitabine is considered investigational and this study will help in determining if their activity and toxici...

What is the current status of trial NCT04039867?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2005-01-20. Estimated completion is 2011-10-06.

What interventions are being tested in trial NCT04039867?

The interventions under investigation include: Oxaliplatin with Gemcitabine (DRUG).

Who is sponsoring clinical trial NCT04039867?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.